Biotech entity
Every one of those 2 sits in a single category, pharma. Of the tracked stories, 1 of 2 also mention Arcturus Therapeutics, the most common co-covered peer. Source depth averages 2 original sources per story, versus 3.1 across the same-window beat baseline.
Last mentioned: Mar 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, pharma. Of the tracked stories, 1 of 2 also mention Arcturus Therapeutics, the most common co-covered peer. Source depth averages 2 original sources per story, versus 3.1 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 5.9. We currently track 2 Biotech stories that mention Rigel Pharmaceuticals, published between March 2, 2026 and March 5, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 35 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Rigel Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Rigel Pharmaceuticals and Cumberland Pharmaceuticals reported Q4 results that emphasize commercial execution and a shift toward sustainable profitability. Both companies are leveraging core hospital and oncology assets to navigate a market that increasingly rewards revenue-generating biotechs over speculative R&D.
Arcturus Therapeutics and Rigel Pharmaceuticals are set to report Q4 2025 results, highlighting a pivotal year for mRNA platform validation and oncology market expansion. Investors are focused on Arcturus's sa-mRNA commercial progress in Japan and Rigel's sales trajectory for its flagship hematology treatments.
Rigel Pharmaceuticals is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
